Next generation sequencing (NGS) is currently changing the treatment regime for ICCA with new treatments for the recently detected mutations IDH1 and FGFR2 (Ivosidenib and Pemigatinib) showing promising results [44]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.